However, despite the initially high rates of response to these ALK‐TKIs, resistant tumor cells can develop due to secondary mutations in the ALK tyrosine kinase domain, activation of bypass signaling pathways or other alterations that cause phenotypic changes, loss of target, or loss of target dependency [3]. The gene discussed is ALK; the disease is neoplasm.